Dioxane

Dioxane

SCHEMBL6985191

C1COCCO1.COC(OC)OC

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.43
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dioxane SCHEMBL4888055 0.87 TTR (0.38) TTR
SCHEMBL27808905 0.87
Tetrahydrofuran SCHEMBL3866495 0.87 ALDH1A1 (0.50)
Dioxane SCHEMBL8962544 0.76
Dioxane SCHEMBL4481844 0.76 TTR (0.40) TTR
SCHEMBL4442942 0.76
SCHEMBL6919 0.76
SCHEMBL4888046 0.74 ALDH1A1 (0.42)
SCHEMBL29071846 0.71
Oxirane SCHEMBL45627 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP claimed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US claimed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US claimed
US-20020147230-A1 Aminal Diones as potassium channel openers ABBOTT LABORATORIES 2002-10-10 US claimed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO claimed
CN-101998932-B Novel precursor for preparing lithium composite transition metal oxide LG CHEMICAL LTD 2013-05-01 CN disclosed
CN-102983320-A Lithium secondary battery LG CHEMICAL LTD 2013-03-20 CN disclosed
CN-101765934-B Positive electrode active material for lithium secondary battery, method for producing same, and lithium secondary battery NIPPON CHEMICAL IND 2013-03-06 CN disclosed
CN-102484250-A Positive Electrode Active Material, Method For Producing Same, And Nonaqueous Electrolyte Secondary Battery Using Same SUMITOMO METAL MINING CO JP 2012-05-30 CN disclosed
CN-101601163-B Lithium secondary battery with improved high-temperature cycle life characteristics LG CHEMICAL LTD 2011-11-16 CN disclosed
CN-101998932-A Novel precursor for preparing lithium composite transition metal oxide LG CHEMICAL LTD 2011-03-30 CN disclosed
CN-101765934-A Positive electrode active material for lithium secondary battery, method for producing same, and lithium secondary battery NIPPON CHEMICAL IND 2010-06-30 CN disclosed
CN-101601163-A Lithium secondary battery with improved high-temperature cycle life characteristics LG CHEMICAL LTD (KR) 2009-12-09 CN disclosed
CN-100499213-C Non-aqueous electrolyte secondary battery MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2009-06-10 CN disclosed
CN-1897332-A Non-aqueous electrolyte secondary battery MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2007-01-17 CN disclosed
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP disclosed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US disclosed
US-20020147230-A1 Aminal Diones as potassium channel openers ABBOTT LABORATORIES 2002-10-10 US disclosed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147230-A1 Aminal Diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 TTR 2975/4885MEN1 773/4885KMT2A 1875/4885
US-20020165264-A1 Aminal diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 TTR 2975/4885MEN1 773/4885KMT2A 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.